Neuralink has announced its receipt of authorization in the United States to conduct a feasibility study for its brain-computer interface (BCI) technology. This new trial will assess the capability of the Elon Musk-supported company’s N1 BCI implant in manipulating an experimental assistive robotic arm. In a post on X— the social media platform previously known as Twitter and now owned by Musk—Neuralink disclosed plans for cross-enrollment between its existing PRIME study and the newly initiated CONVOY study.
The “Telepathy” BCI implant is currently undergoing evaluation to determine its potential in allowing individuals with quadriplegia to control devices through thought alone. The implant, which is rechargeable from a distance, is accompanied by electrodes embedded further into the brain. Neuralink also features an R1 robot for implanting the BCI system while maintaining a safe distance from blood vessels.
“We’re thrilled to unveil the approval and introduction of a new feasibility trial to broaden the scope of BCI capabilities using the N1 Implant to interact with an investigational robotic arm,” the company stated. “This marks a crucial step in not only restoring digital autonomy but also enhancing physical independence.”
In January, the company successfully completed its first human implant as a component of the PRIME study, demonstrated by Noland Arbaugh’s nine-minute live session maneuvering a computer cursor and playing chess online using the Neuralink BCI. The company also outlined additional human implant procedures planned for last summer. Recently, Canadian authorities have also approved Neuralink’s exploration of its BCI technology.
Experts estimate the total addressable market (TAM) in the United States for BCI technology to reach around $400 billion. Discover more about BCIs and some of the key players in this innovative field HERE.